Trial Profile
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Depatuxizumab mafodotin (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie
- 01 Dec 2017 Results of Depatuxizumab-mafodotin monotherapy in patients with recurrent glioblastoma (n=66) published in the Cancer Chemotherapy and Pharmacology
- 06 Jul 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results (n=126) assessing safety and efficacy of ABT-414 with or without temozolomide in patients with recurrent glioblastoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.